OBJECTIVE： To investigate the therapeutic efficacy of edaravone combined with citicoline sodium on acute cerebral infarction and its effects on the levels of oxidative stress and inflammatory factors. METHODS： 108 patients with acute cerebral infarction were randomly divided into edaravone group （single group） and edaravone+citicoline sodium group （drug combination group）， with 54 cases in each group. Based on routine treatment， single group was given Edaravone injection 30 mg added into 100 ml 0.9％ Sodium chloride injection intravenously， bid， used up within 30 min each time； drug combination group was additionally given Citicoline sodium injection 0.5 g added into 250 ml 0.9％ Sodium chloride injection intravenously， qd， on the basis of single group. Treatment course of 2 groups lasted for 2 weeks. NIHSS， HDS， Barthel index， oxidant stress indicator and inflammatory factors were compared between 2 groups before and after treatment. RESULTS： After treatment， the effective rate of NIHSS in drug combination group was 81.48％， which was significantly higher than single group （53.70％）， with statistical significance  （χ2＝9.511， P＝0.002）. HDS score and Barthel index of 2 groups were significantly increased after treatment， especially in drug combination group， with statistical significance （P＜0.05）. Compared with before treatment， contents of MDA and ET-1 in 2 groups were decreased significantly， while SOD activity and NO content were increased significantly； the inflammatory cytokines IL-6， IL-8， IL-12 and IL-16， TNF-α were all decreased gradually， with statistical significance （P＜0.05）； the improvement of each indicator in drug combination group was more significant than single group， with statistical significance （P＜0.05）. CONCLUSIONS： Edaravone combined with citicoline sodium show good therapeutic efficacy in the treatment of acute cerebral infarction， can decrease the levels of oxidative stress and inflammation and promote the recovery of the neurological function and the daily living ability.